BioSpace News Archive

Helius Medical Technologies, Inc. announced that it has received a letter of intent from the Québec Ministry of Health and Social Services for the purchase of 30 Portable Neuromodulation Stimulator devices as part of an initiative to assess the value of using PoNS to treat patients suffering symptoms due to stroke.

PepGen Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the full clinical hold and cleared the Company’s Investigational New Drug Application (IND) to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1) in the U.S.

Kraig Biocraft Laboratories, Inc. today announced that it hired key scientists from the University of Notre Dame (“UND”) spider silk research lab following the retirement of Dr. Malcolm Fraser, Professor Emeritus.

Entrada Therapeutics, Inc. today announced it will participate in the following two investor conferences.

Sharecare (Nasdaq: SHCR ), the digital health company that helps people manage all their health in one place, today announced that it will report third quarter fiscal 2023 financial results on Thursday, November 9, 2023, before the market opens.

HanAll Biopharma and Daewoong Pharmaceutical marked a pivotal step forward in the development of HL192 (ATH-399A) for the potential treatment of Parkinson’s Disease in collaboration with NurrOn Pharmaceuticals.

Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced multiple abstracts to be presented at IDWeek 2023 in Boston, Massachusetts (October 11-15, 2023).

Kuros Biosciences, a leader in next-generation bone graft technologies, provides an update on its commercial activities for the first nine months of 2023 and announces changes and a transition in responsibilities within the Executive Management.

BIOCAPTIVA Ltd announces initiation of an ex-vivo study to establish if, using its BioCaptis device, pleural fluid cfDNA can be isolated from exudative pleural fluid samples in sufficient quantities for downstream DNA analysis to improve pleural disease diagnosis.

Alvotech announced that the US Food and Drug Administration has issued a complete response letter for Alvotech’s Biologics License Application for AVT04, a biosimilar candidate to Stelara®.